9/18/2017 1 Lung Cancer Treatment Updates Val R. Adams, Pharm.D., FCCP, BCOP Associate Professor Univeristy of Kentucky, Markey Cancer Center Objectives • Differentiate the mechanism of action for recently approved lung cancer therapies. • Recall the role in therapy of current and emerging targeted therapies for the treatment of metastatic non‐small cell lung cancer. • Recognize the response rate and expected time to respond for the new immunotherapy. • Identify strategies to prevent and manage adverse events related to the new therapies. 18.1 55.6 28.9 4.5 100 16 22 57 0 10 20 30 40 50 60 70 80 90 100 All Lung CA Localized Regional Advanced Lung Cancer Stage at Diagnosis and 5 Year Survival 5 Year Suvival (%) Spread at Diagnosis (%) Spread of lung cancer disease at diagnosis and corresponding 5 year survival in the United States (SEER Database https://seer.cancer.gov/statfacts/html/lungb.html accessed 8/14/2017)
16
Embed
Cancer Treatment Updates - Northeast Kentucky AHEC...Lung Cancer Treatment Updates Val R. Adams, Pharm.D., FCCP, BCOP Associate Professor Univeristy of Kentucky, Markey Cancer Center
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
9/18/2017
1
Lung Cancer Treatment UpdatesVal R. Adams, Pharm.D., FCCP, BCOP
Associate Professor
Univeristy of Kentucky, Markey Cancer Center
Objectives
• Differentiate the mechanism of action for recently approved lung cancer therapies.
• Recall the role in therapy of current and emerging targeted therapies for the treatment of metastatic non‐small cell lung cancer.
• Recognize the response rate and expected time to respond for the new immunotherapy.
• Identify strategies to prevent and manage adverse events related to the new therapies.
18.1
55.6
28.9
4.5
100
1622
57
0
10
20
30
40
50
60
70
80
90
100
All Lung CA Localized Regional Advanced
Lung Cancer Stage at Diagnosis and 5 Year Survival
5 Year Suvival (%) Spread at Diagnosis (%)
Spread of lung cancer disease at diagnosis and corresponding 5 year survival in the United States (SEER Database https://seer.cancer.gov/statfacts/html/lungb.html accessed 8/14/2017)
9/18/2017
2
The Increasing Complexity if Making Tx Decisions
Lung Cancer
Targetable Mutations
20%
10%
70%
HISTOLOGYSquamous Cell Large Cell Adenocarcinoma
BRAF +2%
ROS1+1%
ALK+5%
EGFR +15%
KRAS30%
Other47%
BRAF + ROS1+ ALK+ EGFR + KRAS Other
Kohno, T. et al. Translational Lung Cancer Research. 2015; 4:156‐64
Borghaei H, , et al. N Eng J Med 2015;373:1627‐1639. Brahmer J, et al. N Eng J Med ;2015;373(2):123‐135. Rittmeyer A, et al. Lancet. 2017;389:255‐265. Herbst RS, et al. Lancet. 2016;387(10027):1540‐1550..
Drug (study) Comparisons PFS Overall Survival
Atezolizumab
(OAK)
Atezolizumab 1200 mg IV q3week
vs.
Docetaxel 75 mg/m2 IV q3week
Median 2.8 months vs.
4 months
Median 13.8 months
vs. 9.6 months
(p = 0.0003)
Nivolumab
(CheckMate 017)
Squamous Histology
Nivolumab 3mg/kg IV q2week
vs.
Docetaxel 75 mg/m2 IV q3week
Median 3.5 months vs.
2.8 months
Median 9.2 months vs.
6.0 months
(p < 0.001)
Nivolumab
(CheckMate 057)
Non‐Squamous
Nivolumab 3mg/kg IV q2week
vs.
Docetaxel 75 mg/m2 IV q3week
Median 2.3 months vs.
4.2 months
Median 12.2months
vs. 9.4 months
(p =0.002)
Pembrolizumab
(KEYNOTE‐010)
Pembrolizumab 2 mg/kg IV q3week
vs.
Docetaxel 75 mg/m2 IV q3week
Median 3.9 months vs.
4 months
Median 10.4months
vs. 8.5 months
(p = 0.0008)
Recent Update PACIFIC Trial
Durvalumab after chemoradiotherapy Stage III
Antonia, SJ, et al. N Engl J Med. epub Sept 8, 2017
Patterns of Response to PembrolizumabObserved in Advanced Melanoma
Hodi, FS, et al. J Clin Oncol 2016;34:1510‐7.
9/18/2017
6
RECISTUnidimensional Measurement
irRECISTBidimensional Measurement
CR Disappearance of all lesions
PR≥ 30% decrease in tumor burden compared with baseline†
≥50% decrease in tumor burden compared with baseline†
SD Not PR, CR, or PD
PD
≥ 20% + 5-mm absolute increase in tumor burden comparedwith nadirAppearance of new lesions or progression of nontarget lesions
≥ 25% increase in tumor burden compared with baseline,nadir, or reset baseline†New lesions added to tumor burden†
• For atezolizumab, other immune‐mediated AEs (any grade) included:
• AST increased (4%)
• ALT increased (4%)
• Pneumonitis (2%)
• Colitis (1%)
• Hepatitis (1%)
ALT = alanine aminotransferase; AST = aspartate aminotransferase. Spira et al. J Clin Oncol. 2015;33:abstract 8010.
Dry skin, stomatitis, and nail disorder were additional AEs with ≥5% higher frequency with docetaxel. Safety population includes patients who received any amount of either study treatment. Data cut-off January 30, 2015
Immune‐Related Adverse Events
• Assume new symptoms are autoimmune and drug related if all other causes have been ruled out
• Can affect any organ system
• Early recognition, evaluation, and treatment are critical to adequate management and opportunity for re‐treatment.
Management of Immune‐Related AEs Algorithm
Management dose represents steroid doseGrade 2 is prednisoneGrade 3/4 toxicity is IV methylprednisoloneHRT = Hormone Replacement Therapy
Eigentler, TK, et al. Ca Treat Rev 2016;45:7‐18
9/18/2017
8
Precision Medicine/Targeted Therapy
Lung Cancer
Patient CaseSJ is a 61 yo WF who presents with NSCLC
HPI: After failing antibiotics a CXR revealed a left lower lobe mass– FNA confirmed adenocarcinoma of the lung
PMH: N/A
FH/SH: Married w/ two sons 28 and 34 (none smoker)
Drug History: NKDA
PE: Findings consistent with lung cancer – otherwise WNL (PS 0‐1)
Labs: Hepatic, renal, and chemistry levels WNL
Radiology: Multiple lesions in the liver– stage IV
Genetics: KRas – WT, EGFR exon 19 deletion, no ALKrearrangement, no ROS1 rearrangement, PD‐L1 unknown
What Treatment would you recommend?
1. None
2. Pembrolizumab
3. Carboplatin – paclitaxel – Bev
4. Erlotinib
5. Crizotinib
9/18/2017
9
OPTIMAL = Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive NSCLC; G/C = Gemcitabine/Carboplatin.Zhou C, et al. Lancet Oncol. 2011;12(8):735-742.
OPTIMAL: First‐line Erlotinib is Associated with Longer PFS vs G/C in EGFR Mutant NSCLC
Time (months)
Pro
gre
ssio
n-f
ree
surv
ival
(%
)
100
60
40
20
0
80
0 5 10 15 20
Erlotinib (N=82)Gemcitabine plus carboplatin (N=72)
HR 0.16 (95% CI 0.10 – 0.26)Log-rank p<0.0001
Number at riskErlotinib 82 70 51 20 2
72 26 4 0 0Gemcitabine pluscarboplatin
First Line EGFR TKIAgents N Outcome1 Outcome2 Comment
Gefitinib vs Carbo‐Tax
1217 1 yr PFS 25% vs 7%
Median OS19 mo vs 17 mo
IPASS trial
Erlotinib vs platinum doublet
228 Median PFS10 mo vs 5 mo
Median OS19 mo vs 19 mo
EURTAC trial
Afatinib vs Cisplatin‐Pem
1269 Median PFS11 mo vs 7 mo
Median OS28 mo vs 28 mo
Lung‐LUX3
CHI, A, et al Biomarker Research 2013;1:1‐10, Yang, JC, et al. Lancet Oncol2015;16:141‐51
• Better than Chemo first line based on PFS, OS roughly equivalent likely due to cross‐over.
• Survival curves do not plateau – Resistance develops during treatment.
Resistance to EGFR TKIs
Nguyen, K.H., Kobayashi, S., Costa,k D.B., Clin Lung Cancer 2009;10:281‐9
9/18/2017
10
Comparison to Chemotherapy: AURA3
• Stratification variables• Asian vs non‐Asian
Mok, TS, et al. N Engl J Med 2017;376:629-40
Osimertinib 80 mgPO DailyN=279
Cisplatin or carboplatin +Pemetrexed
repeat every 3 weeks up to 6 cycles – maintenance pemetrexed allowed
N=140
Eligibility:Progression on 1st line EGFR TKIT790M mutationStable CNS metastases w/o steroids
ESMO 2017 Congress: Abstract LBA2. Presented September 8, 2017
Months
FLUARA Results
80
34
76
45
0
10
20
30
40
50
60
70
80
90
ORR Grade 3/4 Toxicity
Osimertinib EGFR SOC
ESMO 2017 Congress: Abstract LBA2. Presented September 8, 2017
Percentage
EGFR + Advanced Disease Summary
Osimertinib monotherapy or 2 sequential oral EGFR TKIs provide a median of 19 ‐ 20 months of disease free survival. Overall survival yet to be determined – With chemotherapy and immunotherapy Median OS could be 3‐4 years
PFS = 10 MonthsPFS = 10 months
PFS = 19 months
9/18/2017
12
ALEX: New Standard is Coming for ALK+
• Primary endpoint – PFS
• Secondary endpoints– ORR– OS– Time to CNS progression– Safety
Treatment Naïve ALK+
Advanced DzStratified for PS 0 or 1 vs 2
Asian vs Non‐AsianCNS mets
1:1
Alectinib600mg PO twice dailyn = 152
Crizotinib 250 mg PO twice daily
n = 151
Peters, S. et al. N Engl J Med 2017;377:829‐38
Alex Results
Peters, S. et al. N Engl J Med 2017;377:829‐38
Median PFSAlectinib = 25.7 monthsCrizotinib = 10.4 months
Schiller, JH, et.al. N Engl J Med 2002;346:92‐8 Peters, S. et al. N Engl J Med 2017;377:829‐38Shaw, A., et al. N Engl J Med 2014;371:1963‐71 Planchard, D., et al Lancet Oncol 2016;17:984‐93Reck, M., et al. N Engl J Med 2016;375:1823‐33 ESMO 2017 Congress: Abstract LBA2. Presented September 8, 2017
The Best Science Requires Implementation
Make Sure Patients Get Tested!!!
Percent of Patients w/Lung Cancer Not Tested in 2016